Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience

Clicks: 189
ID: 270618
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #216 of 1,084 articles by views in clinical infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In a real-life clinical setting, we found that receipt of neutralizing monoclonal antibody (NmAb) treatment significantly reduced hospital utilization among pat
Reference Key
paulclinicalneutralizing Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Verderese, John Paul;Stepanova, Maria;Lam, Brian;Racila, Andrei;Kolacevski, Andrej;Allen, David;Hodson, Erin;Aslani-Amoli, Bahareh;Homeyer, Michael;Stanmyre, Sarah;Stevens, Helen;Garofalo, Stephanie;Henry, Linda;Venkatesan, Chapy;Gerber, Lynn H;Motew, Steve J;Jones, J Stephen;Younossi, Zobair M;
Journal clinical infectious diseases
Year Year not found
DOI
DOI not found
URL
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab579/6309036?searchresult=1
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.